Review



autologous cd34+-enriched cell fraction strimvelis  (Glaxo Smith)

 
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Glaxo Smith autologous cd34+-enriched cell fraction strimvelis
    FDA/EMA approved gene therapy product for rare monogenic diseases
    Autologous Cd34+ Enriched Cell Fraction Strimvelis, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/strimvelis/pmc11222908-222-7-8
    Average 90 stars, based on 1 article reviews
    autologous cd34+-enriched cell fraction strimvelis - by Bioz Stars, 2026-11
    90/100 stars

    Images

    1) Product Images from "Development of orphan drugs for rare diseases"

    Article Title: Development of orphan drugs for rare diseases

    Journal: Clinical and Experimental Pediatrics

    doi: 10.3345/cep.2023.00535

    FDA/EMA approved gene therapy product for rare monogenic diseases
    Figure Legend Snippet: FDA/EMA approved gene therapy product for rare monogenic diseases

    Techniques Used: Plasmid Preparation, In Vivo, Ex Vivo, Mutagenesis, Modification, Variant Assay

    Related Articles

    Transduction:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Retroviral:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Plasmid Preparation:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Sequencing:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Transplantation Assay:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Virus:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Genetically Modified:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Ex Vivo:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Injection:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Derivative Assay:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Muscles:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Selection:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Clinical Proteomics:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Titration:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Immunopeptidomics:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    In Vitro:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    In Vivo:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.

    Drug discovery:

    Article Title: Characteristics of Medical Products Comprising Human Cells, Genes, or Tissues Developed in Japan and the European Union Compared via Public Assessment Reports
    Article Snippet: , Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence , Strimvelis® , Adenosine deaminase (ADA)-severe combined immunodeficiency , GlaxoSmithKline Trading Services , ○ , ○ , Autologous.



    Similar Products

    96
    Miltenyi Biotec cd34 fraction
    Cd34 Fraction, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/CD34+MicroBead+Kit+UltraPure%2C+human/bio_rxiv__64898__2025__12__22__695871-246-1-6
    Average 96 stars, based on 1 article reviews
    cd34 fraction - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    99
    Miltenyi Biotec cd34 cell fractions
    Cd34 Cell Fractions, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/CD34-VioBlue/us12203096-489-17-31
    Average 99 stars, based on 1 article reviews
    cd34 cell fractions - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    Miltenyi Biotec cd34 cell fraction
    Cd34 Cell Fraction, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/CD34-VioBlue/pm39277669-53-1-17
    Average 99 stars, based on 1 article reviews
    cd34 cell fraction - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    99
    Qiagen cd34 cell fraction
    Cd34 Cell Fraction, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/miRNeasy+Micro+Kit/pmc11604037-358-7-18
    Average 99 stars, based on 1 article reviews
    cd34 cell fraction - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    90
    Glaxo Smith autologous cd34+-enriched cell fraction strimvelis
    FDA/EMA approved gene therapy product for rare monogenic diseases
    Autologous Cd34+ Enriched Cell Fraction Strimvelis, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd34++fraction/strimvelis/pmc11222908-222-7-8
    Average 90 stars, based on 1 article reviews
    autologous cd34+-enriched cell fraction strimvelis - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    Image Search Results


    FDA/EMA approved gene therapy product for rare monogenic diseases

    Journal: Clinical and Experimental Pediatrics

    Article Title: Development of orphan drugs for rare diseases

    doi: 10.3345/cep.2023.00535

    Figure Lengend Snippet: FDA/EMA approved gene therapy product for rare monogenic diseases

    Article Snippet: For instance, an autologous CD34+-enriched cell fraction, Strimvelis (GlaxoSmithKline plk, London, UK), which contains CD34+ cells transduced with a retroviral vector that encodes the human ADA cDNA sequence for ADA deficiency (introduced in 2016), and voretigene neparvovec-rzyl (Luxturna, Spark Therapeutics, Philadelphia, USA), for retinal dystrophy caused by mutations in the RPE65 gene, were approved by the FDA in 2017 at a cost of $850,000 per eye [ ].

    Techniques: Plasmid Preparation, In Vivo, Ex Vivo, Mutagenesis, Modification, Variant Assay